PRIVA-VALACYCLOVIR TABLET
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
27-06-2015
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE)
Available from:
PHARMAPAR INC
ATC code:
J05AB11
INN (International Name):
VALACICLOVIR
Dosage:
500MG
Pharmaceutical form:
TABLET
Composition:
VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500MG
Administration route:
ORAL
Units in package:
30/100
Prescription type:
Prescription
Therapeutic area:
NUCLEOSIDES AND NUCLEOTIDES
Product summary:
Active ingredient group (AIG) number: 0128626001; AHFS:
Authorization status:
CANCELLED POST MARKET
Authorization date:
2022-07-29
Summary of Product characteristics
_Priva-VALACYCLOVIR _
_ _
_Page 1 of 39 _
PRODUCT MONOGRAPH
PR
PRIVA-VALACYCLOVIR
valacyclovir (as valacyclovir hydrochloride)
Valacyclovir Tablets 500 mg USP
Antiviral Agent
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
June 3, 2015
Mont-Royal
QC H4T 1E2
Control#: 184603
_Priva-VALACYCLOVIR _
_ _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
3
WARNINGS AND PRECAUTIONS
...........................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................................
13
DOSAGE AND ADMINISTRATION
.......................................................................................................
14
OVERDOSAGE
.........................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
16
STORAGE AND STABILITY
...................................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
18
PART II: SCIENTIFIC INFORMATION
.........................................
Read the complete document
